ADVFN Logo
Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.

ALLK Allakos Inc

1.1881
-0.0519 (-4.19%)
Jun 15 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 340,545
Bid Price 1.10
Ask Price 1.52
News -
Day High 1.23

Low
0.9799

52 Week Range

High
5.64

Day Low 1.16
Company Name Stock Ticker Symbol Market Type
Allakos Inc ALLK NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.0519 -4.19% 1.1881 00:00:03
Open Price Low Price High Price Close Price Prev Close
1.23 1.16 1.23 1.16 1.24
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
2,493 340,545 $ 1.18 $ 401,475 - 0.9799 - 5.64
Last Trade Time Type Quantity Stock Price Currency
17:22:22 formt 2,000 $ 1.1881 USD

Allakos Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
101.93M 87.87M - 0 -185.7M -2.11 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Allakos News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No ALLK Message Board. Create One! See More Posts on ALLK Message Board See More Message Board Posts

Historical ALLK Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week1.171.331.101.25535,4240.01811.55%
1 Month1.431.511.101.29488,225-0.2419-16.92%
3 Months1.291.510.97991.23462,611-0.1019-7.90%
6 Months3.223.4050.97991.531,067,346-2.03-63.10%
1 Year5.035.640.97992.301,031,237-3.84-76.38%
3 Years94.62112.870.97998.751,330,083-93.43-98.74%
5 Years41.33157.980.979920.14935,510-40.14-97.13%

Allakos Description

Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's lead program, AK002, an antibody that targets Siglec-8, an inhibitory receptor found on eosinophils and mast cells. In preclinical and clinical studies, AK002 has been shown to deplete eosinophils and inhibit mast cells.

Your Recent History

Delayed Upgrade Clock